Kymera Therapeutics, Inc. (KYMR) Stock

Kymera Therapeutics, Inc. (KYMR) is a Healthcare stock trading at $111.09 (as of 2026-07-20), with a market capitalization of $9.14B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Understand Kymera Therapeutics, Inc.: how it makes money

Kymera Therapeutics discovers and develops small molecule therapeutics that selectively degrade disease-causing proteins, and it earns near-term collaboration revenue from partners such as Sanofi.

Near-term dollars appear tied to collaboration revenue (Sanofi and Santa Fe), while the longer-term value driver is clinical execution across programs such as KT-621 (BroADen Phase 1b) and the transition toward later-stage plans.

Revenue by segment (latest quarter)
Sanofi$0.0B
SantaFe$0.0B

Business quality (Weak): Clear scientific program direction and early clinical signals, but current financial scale is very small, and profitability is not yet evident.

Bull case

  • Scientific approach targets selective protein degradation using the body's natural protein degradation system: This is the core therapeutic concept behind Kymera's novel small molecule therapeutics programs.
  • KT-621 clinical progress is underway in the BroADen Phase 1b program: Patients Enrolled in BroADen Phase 1b is 22, and KT-621 BroADen Phase 1b Atopic Dermatitis Patients Evaluated Approximately is 20.
  • Reported biomarker and clinical response signals for STAT6-related degradation and atopic dermatitis endpoints: STAT6 Degradation Achieved Single Ascending Dose Mean Reduction is 95%, Median STAT6 Degradation in Blood Day 29 is 98%, and Eczema Area and Severity Index 50 Responder Rate All Patients is 76%.
  • Advancing development plans beyond Phase 1b are stated: KT-621 BroADen2 Phase 2b Atopic Dermatitis Patients Planned is 200, and BREADTH Phase 2b Planned Enrollment Adult Patients is 264.

Bear case

  • Financial scale is limited in the latest quarter: Revenue_b is reported as 0.0B for the period ending 2026-03-31, with Sanofi Collaboration Revenue at 0.03B and Santa Fe Collaboration Revenue at 0.0B.
  • Profitability remains deeply negative: Operating margin_pct is -244.9.
  • Most programs shown are early-stage or planned stages with outcomes not yet fully demonstrated: IRAK4 is in Phase I clinical trial, and KT-621 advancement includes planned Phase 2b enrollment rather than completed Phase 2b results in the provided facts.
Valuation — source: SEC EDGAR (first-party)
Price$111.09
Market Cap$9.14B
Price / Book5.94
Price / Sales177.52
FCF Yield-2.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$39.21M
Net Margin-794.0%
Revenue Growth (YoY)55.5%
EPS Growth (YoY)-13.4%
FCF Growth (YoY)12.1%
Financial Health — source: SEC EDGAR
Altman Z-Score32.40 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.1
Industry P/E (Pharmaceutical Products)16.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($974.49M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEONello Mainolfi
Employees208
CountryUS
IPO Date2020-08-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Exelixis, Inc. (EXEL)
  • Apogee Therapeutics, Inc. (APGE)
  • Krystal Biotech, Inc. (KRYS)
  • Halozyme Therapeutics, Inc. (HALO)
  • Immunovant, Inc. (IMVT)
  • Vaxcyte, Inc. (PCVX)
  • ImmunityBio, Inc. (IBRX)
  • CG Oncology, Inc. Common stock (CGON)
KYMR earnings history · KYMR institutional & insider holders · KYMR KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.